Chemomab Therapeutics Ltd.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | — | — | — |
| 2026-03-19 | -0.01 | — | +70.00% |
| 2025-11-20 | -0.04 | — | +90.00% |
| 2025-08-14 | -0.04 | -0.02 | +60.00% |
| 2025-05-15 | -0.04 | -0.03 | +30.00% |
| 2025-03-03 | -0.04 | -0.03 | +20.00% |
| 2024-11-14 | -0.04 | -0.04 | — |
| 2024-08-21 | -0.04 | 0.05 | +230.00% |
| 2024-05-09 | -0.06 | -0.06 | +6.67% |
| 2024-03-07 | -0.08 | -0.05 | +35.00% |
| 2023-11-09 | -0.08 | -0.07 | +15.00% |
| 2023-08-14 | -0.16 | -0.14 | +10.00% |
| 2023-05-11 | -0.14 | -0.16 | -14.29% |
| 2023-02-21 | -0.12 | -0.14 | -20.00% |
| 2022-11-10 | -0.92 | -0.14 | +84.78% |
| 2022-08-12 | -0.72 | -0.11 | +85.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CMMB | +24.38% | +11.54% | +21.21% | -62.12% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +21.41% | +16.18% | +24.66% | -74.81% |